The move means that vaccines for this age group will not be available in the coming weeks, a setback for parents eager to vaccinate their young children.

Pfizer said on Friday that it will wait for its data on a three-dose series of the vaccine, because it believes three doses “may provide a higher level of protection in this age group.” Data on the third dose is expected in early April, the company said.